The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

A clinical social worker describes how the application of positive psychology interventions may improve well-being and ...

Researchers sought to determine trends and future patterns for liver, pancreatic, colorectal, stomach, and esophageal cancers in the US.

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

HealthDay News — For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The median progression-free survival was 10.7 months, and the median intracranial progression-free survival was 16.1 months. The combination of brain radiotherapy and chemoimmunotherapy could be a ...

An umbrella review of components of reliance among patients with cancer compared 20 instruments to find 3 that are ideal for these patients.